Provide affordable short-read sequencing for every genomics lab, from bench to core facility.
Launched 2022; VITARI variant 2026. Primary genomic and multiomics platform.
Updated 9 Jun 2026Checked 11 Oct0 updates this week
Standardized protocols reduce hands-on time vs. competitors.
High-quality reads at low cost per genome. Suits assembly, variant calling, and expression.
Element adds RNA, protein and spatial modules for integrated multiomics workflows.
| Spec | AVITI |
|---|---|
| Technology | Short-read DNA sequencingR (reported) |
| Instrument form factor | Benchtop (AVITI); higher-throughput (VITARI)R (reported) |
R reported by the company
Element Biosciences
AVITI sequencing platform, short-read sequencer
Element Biosciences builds DNA sequencing platforms. AVITI offers short-read sequencing at lower cost. VITARI is a high-throughput benchtop variant. Founded 2017 in San Diego; Samsung led $175M Series E in June 2026.
elementbiosciences.com (opens elementbiosciences.com)Company profile →